Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

European journal of clinical pharmacology - 1 Dec 2005

Funck-Brentano Christian, Boëlle Pierre-Yves, Verstuyft Céline, Bornert Célia, Becquemont Laurent, Poirier Jean-Marie

Abstract excerpt

OBJECTIVE: Dextromethorphan (DEM) shares part of the adverse event profile of opioids and is widely used as a probe drug for CYP2D6 phenotyping and for the assessment of CYP2D6 activity. It has also been used to assess CYP3A4 activity. This study examined the influence of anthropometric variables, oral contraceptives, smoking habits, mu-opioid receptor and MDR1 genetic polymorphisms and components of the DEM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Dextromethorphan

Share to MET gene

Share to Genotype

Share to Logistic Models

Source

Identifiers

PMID: 16315033
DOI: 10.1007/s00228-005-0051-5

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.PMID 16315033Read ↗

In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.Semantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphism in eastern Indian population.Semantic proximity Read ↗

Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.Semantic proximity Read ↗

Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.Semantic proximity Read ↗

Dextromethorphan metabolic phenotyping in an Iranian population.Semantic proximity Read ↗

Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.Semantic proximity Read ↗

Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.